Petosemtamab with Chemotherapy for Colorectal Cancer

Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)

Recruiting Phase 3 Interventional Study
Colorectal Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
600 (estimated)
Sponsor
Genmab · Industry
Who this trial is looking for

This trial is looking for people with colorectal cancer that has come back or spread and cannot be removed by surgery. Participants will take either petosemtamab with chemotherapy or standard treatment options with chemotherapy, with regular visits for testing.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with colorectal adenocarcinoma that is recurrent or has spread.
  • I have documented normal KRAS and NRAS genes.
  • I have received no more than one prior treatment for my cancer.
  • I am eligible for specific chemotherapy treatments.
  • I have confirmed disease progression after my last treatment.

You may not be able to join if

  • I have a BRAF V600 mutation or certain other specific tumor markers.
  • I have already taken medications that target the epidermal growth factor receptor.
  • I have had previous treatment with irinotecan or oxaliplatin in this setting.
  • I have known complete DPD deficiency.
  • I have certain UGT1A1 gene variations.
  • I have cancer that is not colorectal adenocarcinoma.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial
The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer that has recurred after previous treatment and that cannot be safely removed by surgery or has spread to other parts of the body. Participants will receive either petosemtamab + doctor's choice of chemotherapy (mFOLFOX6 or FOLFIRI) or doctor's choice of standard-of-care …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Key Inclusion Criteria: * Histologically or cytologically confirmed colorectal adenocarcinoma that is recurrent, unresectable or metastatic. * Must have documented KRAS and NRAS wt CRC, as determined by medical record of results from local testing or as assessed by central testing. Next-generation …
Contacts

Genmab Trial Information

+4570202728

clinicaltrials@genmab.com

CONTACT